Total Valuation
SAMSUNG PHARMACEUTICAL.CO.,Ltd. has a market cap or net worth of ₩117.65B. The enterprise value is ₩134.50K.
Market Cap₩117.65B
Enterprise Value₩134.50K
Share Statistics
SAMSUNG PHARMACEUTICAL.CO.,Ltd. has 94,162,080 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding94,162,080
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is -13.63%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)-13.63%
Return on Capital Employed (ROCE)-0.16
Revenue Per Employee191.98M
Profits Per Employee48.10M
Employee Count240
Asset Turnover0.28
Inventory Turnover3.07
Valuation Ratios
The current PE Ratio of SAMSUNG PHARMACEUTICAL.CO.,Ltd. is ―. SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s PEG ratio is -0.07.
PE Ratio―
PS Ratio3.13
PB Ratio1.19
Price to Fair Value1.19
Price to FCF-14.26
Price to Operating Cash Flow-13.37
PEG Ratio-0.07
Income Statement
In the last 12 months, SAMSUNG PHARMACEUTICAL.CO.,Ltd. had revenue of 46.07B and earned 11.55B in profits. Earnings per share was 122.66.
Revenue46.07B
Gross Profit14.64B
Operating Income-19.46B
Pretax Income11.55B
Net Income11.55B
EBITDA-18.06B
Earnings Per Share (EPS)122.66
Cash Flow
In the last 12 months, operating cash flow was -8.80B and capital expenditures -13.48B, giving a free cash flow of -9.75B billion.
Operating Cash Flow-8.80B
Free Cash Flow-9.75B
Free Cash Flow per Share-103.57
Dividends & Yields
SAMSUNG PHARMACEUTICAL.CO.,Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.32
52-Week Price Change-21.14%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)475.03K
Important Dates
SAMSUNG PHARMACEUTICAL.CO.,Ltd. upcoming earnings date is Nov 18, 2026, TBA (Confirmed).
Last Earnings DateAug 14, 2026
Next Earnings DateNov 18, 2026
Ex-Dividend Date―
Financial Position
SAMSUNG PHARMACEUTICAL.CO.,Ltd. as a current ratio of 0.92, with Debt / Equity ratio of 25.74%
Current Ratio0.92
Quick Ratio0.68
Debt to Market Cap0.12
Net Debt to EBITDA-0.36
Interest Coverage Ratio-16.28
Taxes
In the past 12 months, SAMSUNG PHARMACEUTICAL.CO.,Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
SAMSUNG PHARMACEUTICAL.CO.,Ltd. EV to EBITDA ratio is -8.34, with an EV/FCF ratio of -14.90.
EV to Sales3.27
EV to EBITDA-8.34
EV to Free Cash Flow-14.90
EV to Operating Cash Flow-14.98
Balance Sheet
SAMSUNG PHARMACEUTICAL.CO.,Ltd. has ₩9.56B in cash and marketable securities with ₩18.60B in debt, giving a net cash position of -₩9.04B billion.
Cash & Marketable Securities₩9.56B
Total Debt₩18.60B
Net Cash-₩9.04B
Net Cash Per Share-₩96.03
Tangible Book Value Per Share₩1.12K
Margins
Gross margin is 38.51%, with operating margin of -42.23%, and net profit margin of 25.06%.
Gross Margin38.51%
Operating Margin-42.23%
Pretax Margin25.06%
Net Profit Margin25.06%
EBITDA Margin-39.21%
EBIT Margin-42.23%
Analyst Forecast
The average price target for SAMSUNG PHARMACEUTICAL.CO.,Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-2.43%
EPS Growth Forecast-234.71%